Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Assets (2016 - 2026)

Ocular Therapeutix has reported Assets over the past 14 years, most recently at $732.5 million for Q1 2026.

  • For Q1 2026, Assets rose 80.46% year-over-year to $732.5 million; the TTM value through Mar 2026 reached $732.5 million, up 80.46%, while the annual FY2025 figure was $808.1 million, 76.46% up from the prior year.
  • Assets for Q1 2026 was $732.5 million at Ocular Therapeutix, down from $808.1 million in the prior quarter.
  • Over five years, Assets peaked at $808.1 million in Q4 2025 and troughed at $122.6 million in Q2 2023.
  • A 5-year average of $361.6 million and a median of $405.9 million in 2025 define the central range for Assets.
  • Biggest five-year swings in Assets: crashed 31.47% in 2023 and later soared 321.92% in 2024.
  • Year by year, Assets stood at $149.3 million in 2022, then surged by 68.84% to $252.1 million in 2023, then skyrocketed by 81.68% to $457.9 million in 2024, then soared by 76.46% to $808.1 million in 2025, then dropped by 9.35% to $732.5 million in 2026.
  • Business Quant data shows Assets for OCUL at $732.5 million in Q1 2026, $808.1 million in Q4 2025, and $410.9 million in Q3 2025.